The Growing AdAlta Pipeline


We are utilising the power of our i-body technology platform to develop a growing pipeline of i-bodies to treat a range of conditions, with an initial focus on treating fibrotic diseases.

Our lead i-body drug candidate AD-114 has significant anti-fibrotic effects in treating a type of fibrosis of the lung, known as idiopathic pulmonary fibrosis (IPF), and this is our initial focus. AD-114 has also demonstrated its usefulness in treating fibrosis of the eye and we are pursuing this as an additional opportunity for treatment of age-related macular degeneration (wet-AMD).

We have broadened the application of AD-114 to other fibrosis indications, including demonstrating therapeutic applications for fibrosis diseases of the liver and skin, and will now move on to kidney and heart applications.

AD-114 has key advantages for IPF treatment. These include:

  • only targeting diseased human tissue with effects only shown on IPF tissue and no effects displayed on normal lung tissue nor any evidence of off target effects;
  • being more effective than existing IPF approved drugs with greater in vitro efficacy compared to the only approved therapies Nintedanib and Pirfenidone;
  • demonstrated efficacy in multiple animal models showing that AD-114 has both anti-fibrotic and anti-inflammatory effects; and
  • a novel mechanism of action for fibrosis enabling a “first in class” therapy.

AD-114 effective against Idiopathic Pulmonary Fibrosis (IPF)

IPF is a highly lethal and rare disease with current treatment options only demonstrating a reduction in disease progression. There is no cure. A new, more effective, and longer-lasting treatment regime using i-bodies would bring hope to hundreds of thousands of patients worldwide.

AD-114 has completed extensive pre-clinical studies with positive in vitro (in the lab) and in vivo (in animals) data obtained. For example, in animal lung mouse disease models treated with AD-114, collagen content and inflammatory cell infiltration is substantially reduced thereby demonstrating a similar architecture to that of the normal lung.

AdAlta Pipeline

Normal lung tissue

AdAlta Pipeline

IPF lung tissue
(lung disease mouse model)

AdAlta Pipeline

IPF lung tissue + AD-114 dosed for
21 days showing significant recovery

(lung disease mouse model)


AD-114 combats Macular Degeneration in the eye

Wet-AMD (age-related macular degeneration) is a leading cause of vision loss in the world. It destroys the macula, the part of the eye that provides sharp, central vision needed for seeing objects clearly. Millions of people are affected annually.

We have shown that the AD-114 i-body has important anti-fibrotic effects in the eye for patients with this irreversible condition. No-one else has investigated this route to prevent or delay blindness due to this widespread problem.

We were delighted to be awarded a National Health and Medical Research (NHMRC) Development Grant, from the Australian Government, in collaboration with The University of Melbourne, The Centre for Eye Research Australia, Monash University and La Trobe University, to assess the i-body AD-114 drug candidate for treatment in a number of fibrosis-related eye diseases, to support the pre-clinical development of the eye fibrosis indication.

A successful outcome from this program will trigger the potential to progress development of the lead i-body drug candidate AD-114 in a second vitally important area of clinical need.